BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.53), which may not compare to the analyst estimate of ($0.38). Revenue for the quarter came in at $300 million versus the consensus estimate of $295.96 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.